Literature DB >> 20374707

The roles and action mechanisms of p160/SRC coactivators and the ANCCA coregulator in cancer.

Elaine Y C Hsia1, June X Zou, Hong-Wu Chen.   

Abstract

Chromosomal aberrations involving genes encoding members of the p160/SRC transcriptional coactivator family such as AIB1/ACTR and TIF2 implicated the coactivators in malignancy of human cells. Significant progress has been made in the last decade toward uncovering their roles in the development and progression of solid tissue tumors as well as leukemia and understanding of the underlying molecular mechanisms. Here, we review their genetic aberrations and dysregulation in expression in breast cancer, prostate cancer, and other nonhormone-responsive cancers. The experimental evidence gathered from studies using cell culture and animal models strongly supports a critical and, in some circumstances, their oncogenic function. We summarize results that the SRCs may contribute to tumorigenesis and disease progression through transcription factors such as E2F, PEA3, and AP-1 and through an intimate control of signaling pathways of growth factors-Akt and the receptor tyrosine kinases. The finding that a recently identified nuclear receptor coregulator ANCCA, like the SRCs, is frequently overexpressed in many types of cancers again underscores their broader roles in cancer.
Copyright © 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20374707     DOI: 10.1016/S1877-1173(09)87008-7

Source DB:  PubMed          Journal:  Prog Mol Biol Transl Sci        ISSN: 1877-1173            Impact factor:   3.622


  7 in total

1.  ANCCA/ATAD2 overexpression identifies breast cancer patients with poor prognosis, acting to drive proliferation and survival of triple-negative cells through control of B-Myb and EZH2.

Authors:  Ekaterina V Kalashnikova; Alexey S Revenko; Abigael T Gemo; Nicolas P Andrews; Clifford G Tepper; June X Zou; Robert D Cardiff; Alexander D Borowsky; Hong-Wu Chen
Journal:  Cancer Res       Date:  2010-09-23       Impact factor: 12.701

Review 2.  Nuclear receptor coregulators as a new paradigm for therapeutic targeting.

Authors:  Elaine Y Hsia; Michael L Goodson; June X Zou; Martin L Privalsky; Hong-Wu Chen
Journal:  Adv Drug Deliv Rev       Date:  2010-10-07       Impact factor: 15.470

Review 3.  Nuclear Receptor Coregulators in Hormone-Dependent Cancers.

Authors:  Hedieh Jafari; Shahid Hussain; Moray J Campbell
Journal:  Cancers (Basel)       Date:  2022-05-13       Impact factor: 6.575

4.  Transcriptional repression of AIB1 by FoxG1 leads to apoptosis in breast cancer cells.

Authors:  Jordan V Li; Christopher D Chien; Jason P Garee; Jianming Xu; Anton Wellstein; Anna T Riegel
Journal:  Mol Endocrinol       Date:  2013-05-09

5.  NEAT1_2 functions as a competing endogenous RNA to regulate ATAD2 expression by sponging microRNA-106b-5p in papillary thyroid cancer.

Authors:  Wei Sun; Xiabin Lan; Hao Zhang; Zhihong Wang; Wenwu Dong; Liang He; Ting Zhang; Ping Zhang; Jinhao Liu; Yuan Qin
Journal:  Cell Death Dis       Date:  2018-03-07       Impact factor: 8.469

6.  Knockdown of ATAD2 Inhibits Proliferation and Tumorigenicity Through the Rb-E2F1 Pathway and Serves as a Novel Prognostic Indicator in Gastric Cancer.

Authors:  Xuan Zhou; Huihui Ji; Dongxue Ye; Hong Li; Fen Liu; Haiyan Li; Jin Xu; Yujun Li; Fenggang Xiang
Journal:  Cancer Manag Res       Date:  2020-01-15       Impact factor: 3.989

Review 7.  Tumor-Promoting ATAD2 and Its Preclinical Challenges.

Authors:  Haicheng Liu; Qianghai Wen; Sheng Yan; Weikun Zeng; Yuhua Zou; Quanliang Liu; Guoxi Zhang; Junrong Zou; Xiaofeng Zou
Journal:  Biomolecules       Date:  2022-07-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.